Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

10.1007/s10549-010-0788-0

Saved in:
Bibliographic Details
Main Authors: Barrios, C.H., Liu, M.-C., Lee, S.C., Vanlemmens, L., Ferrero, J.-M., Tabei, T., Pivot, X., Iwata, H., Aogi, K., Lugo-Quintana, R., Harbeck, N., Brickman, M.J., Zhang, K., Kern, K.A., Martin, M.
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Article
Published: 2014
Subjects:
Advanced breast cancer
Capecitabine
Sunitinib malate
Tyrosine kinase inhibitor
Online Access:http://scholarbank.nus.edu.sg/handle/10635/110766
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

http://scholarbank.nus.edu.sg/handle/10635/110766

Similar Items